In the Claims:

Please cancel claims 57 and 65, without prejudice, and amend claims 46-48, 50-52, 54, 56, 59-62, 64 and 67, as follows:

46. (Amended) A method for preventing and/or treating an amyloid-related disease in a subject, comprising: administering to the subject an antigenic amount of an all-D amyloid-β peptide, wherein said all-D amyloid-β peptide induces an immune response by said subject against said amyloid-β peptide.

47. (Amended) The method of claim 46, wherein said all-D amyloid-β peptide interacts with at least one region of an amyloid protein, said region being selected from the group consisting of: C-terminal region, β sheet region, GAG-binding site region, cellular adherence region, immunogenic fragments thereof, protein conjugates thereof, immunogenic derivative peptides thereof, immunogenic peptides thereof, and immunogenic peptidomimetics thereof.

48. (Amended) The method of claim 46, wherein said all-D amyloid-β peptide further comprises:

an N-terminal substituent selected from the group consisting of:

hydrogen;

lower alkyl group consisting of acyclic or cyclic having 1 to 8 carbon atoms;

aromatic group;

heterocyclic group; and

acyl group; and

a C-terminal substituent selected from the group consisting of hydroxy, alkoxy, aryloxy, unsubstituted and substituted amino groups.

50. (Amended) The method of claim 48, wherein said all-D amyloid-β peptide further comprises an acid functional group, or a pharmaceutically acceptable salt or ester form thereof.

51. (Amended) The method of claim 48, wherein said all-D amyloid-β peptide is selected from the group consisting of SEQ ID NOS: 1-48.

52. (Amended) The method of claim 51, wherein said all-D amyloid-β peptide is modified by substituting at least one amino acid residue with another amino acid or non-amino acid fragment.

54. (Amended) The method of claim 51, wherein said all-D amyloid-β peptide is modified by removing or inserting at least one amino acid residue.

56. (Amended) A method for preventing and/or treating an amyloid-related disease in a subject, comprising administering to the subject an antigenic amount of a peptide having Formula I:

R'—(P)—R" (I)

wherein

P is an all-D amyloid-β peptide selected from the group consisting of: Aβ(1-42, all-D), C-terminal region, β sheet region, GAG-binding site region, cellular adherence region, immunogenic fragments thereof, protein conjugates thereof, immunogenic derivative peptides thereof, immunogenic peptides thereof, and immunogenic peptidomimetics thereof;

R' is an N-terminal substituent selected from the group consisting of:
hydrogen;
lower alkyl group consisting of acyclic or cyclic having 1 to 8 carbon atoms;
aromatic group;
heterocyclic group; and
acyl group; and

R" is a C-terminal substituent selected from the group consisting of hydroxy group, alkoxy group, aryloxy group, unsubstituted group, and substituted amino group,

wherein said all-D amyloid-β peptide induces an immune response by said subject against said all-D amyloid-β peptide.

59. (Amended) The method of claim 56, wherein said all-D amyloid-β peptide further comprises an acid functional group, or a pharmaceutically acceptable salt or ester form thereof.

60. (Amended) The method of claim 56, wherein said all-D amyloid-β peptide further comprises a base functional group, or pharmaceutically acceptable salt form thereof.

61. (Amended) The method of claim 56, wherein said all-D amyloid-β peptide is selected from the group consisting of SEQ ID NOS: 1-48.

62. (Amended) The method of claim 61, wherein said all-D amyloid-β peptide is modified by substituting one or more amino acid residues with other amino acid or non-amino acid fragment.

64. (Amended) The method of claim 61, wherein said all-D amyloid-β peptide is modified by removing or inserting one or more amino acid residues.

67. (Amended) The method of claim 56, wherein said disease is cerebral amyloid angiopathy.

Please add the following new claims:

104. (New) The method of claim 46, wherein said immune response prevents and/or reduces amyloid fibril formation.

105. (New) The method of claim 46, wherein said immune response prevents and/or reduces amyloid-induced neurodegeneration.

106. (New) The method of claim 46, wherein said immune response prevents and/or reduces amyloid-induced cellular toxicity.

107. (New) The method of claim 56, wherein said immune response prevents and/or reduces amyloid fibril formation.

108. (New) The method of claim 56, wherein said immune response prevents and/or reduces amyloid-induced neurodegeneration.

109. (New) The method of claim 56, wherein said immune response prevents and/or reduces amyloid-induced cellular toxicity.

Pursuant to 37 CFR 1.121(b)(1)(iii), a marked up version of the amended claims showing the changes made appears herein as Appendix A.

REMARKS

Upon entry of the foregoing amendments, claims 46-54, 56, 58-64, 66-68, and 104-109 are pending in the present application.

The Specification was amended to correct a clerical error in three sequences. Basis for this amendment can be found in FIG. 1 of the Specification.

Claims 55 and 69-103 are withdrawn pursuant to the election in the present Response to Restriction Requirement. Claims 57 and 65 are canceled, without prejudice.

Applicants have amended claims 46-48, 50-52, 54, 56, 59-62, and 64 to define that the all-D peptide is an all-D amyloid-β peptide. Support for this amendment is found at page 2, lines 6-8, page 4, lines 6-14, page 8, lines 3-7, and page 14, lines 27-33 of the Substitute Specification filed September 17, 2001. Claims 1, 56, and 67 were further amended, and new claims 104-109